Skip banner and top navigation
National Heart, Lung, and Blood Institute
Home Page   Home » Information for Researchers » NHLBI Research and Policy Listserv

NHLBI Research and Policy Update
Number 70

Message from Dr Susan B. Shurin
Message from NHLBI Director

Message from Dr. Susan B. Shurin

November 10, 2010

Dear Colleagues:

The NIH is launching a new program specifically targeted to the development of therapeutics for rare and neglected diseases.  The Congressionally mandated program, titled Therapeutics for Rare and Neglected Diseases (TRND), is designed to bridge the gap that often exists between a basic research discovery and the testing of new drugs in humans.

TRND is intended to stimulate research collaborations between intramural NIH drug development scientists and research partners such as academic laboratories, non-profit organizations, and pharmaceutical and biotechnology companies working on rare and neglected illnesses.  It will offer research partners that have promising leads or disease/target knowledge access to the expertise and resources they need to develop their leads or targets to a point where private companies would be interested in getting the products to market.

The due date for the first cycle of TRND applications is December 6, 2010.  All applications to the program must be submitted online at

The TRND “flyer”, which provides a brief overview of the program, may be found at:  For more detailed information about the program, please see

Best regards,
Susan B. Shurin, M.D.

bulletAn Archive of the current and past issues is available on the NHLBI Web site.

Two ways to unsubscribe:
  1. Send an e-mail message to: LISTSERV@LIST.NIH.GOV
    and, in the text of your message (not the subject line), write (or copy/paste):

  2. Use the List Web Page
    A) select this link
    B) Enter your e-mail address as it appears in the To: field of the list,
    C) Enter your full name, and
    D) Select the button, Leave the list.